The DOI matches its Crossref record.
Glucose Analog Inhibitors of Glycogen Phosphorylases as Potential Antidiabetic Agents: Recent Developments
Open accessAbstract
Diabetes is among the largest contributors to global mortality through its long term complications. The worldwide epidemic of type 2 diabetes has been stimulating the quest for new concepts and targets for the treatment of this incurable disease. A new target is glycogen phosphorylase (GP), the main regulatory enzyme in the liver responsible for the control of blood glucose levels. One of several approaches to influence the action of GP is the use of glucose derivatives as active site inhibitors. This field of research commenced 10-15 years ago and, due to joint efforts in computer aided molecular design, organic synthesis, protein crystallography, and biological assays, resulted in glucopyranosylidene-spiro-hydantoin 16 (K(i) = 3-4 micro M) as the most efficient glucose analog inhibitor of GP of that time. The present paper surveys the recent developments of this field achieved mainly in the last five years: the synthesis and evaluation of glucopyranosylidene-spiro-thiohydantoin 18 (K(i) = 5 micro M) which has proven equipotent with 16, and is available in gram amounts; furanosylidene- and xylopyranosylidene-spiro-(thio)hydantoins whose ineffectiveness (K(i) > 10 mM) confirmed the high specificity of the catalytic site of GP towards the D-glucopyranosyl unit; "open" hydantoins like methyl N-(1-carboxamido-D-glucopyranosyl)carbamate 37 (K(i) = 16 micro M) and N-acyl-N'-(beta-D-glucopyranosyl)ureas among them the to date best glucose analog inhibitor N-(2-naphthoyl)-N'-(beta-D-glucopyranosyl)urea (35, K(i) = 0.4 micro M) which can also bind to the so-called new allosteric site of GP; C-(beta-D-glucopyranosyl)heterocycles (tetrazole, 1,3,4-oxadiazoles, benzimidazole (K(i) = 11 micro M), and benzothiazole). Iminosugars like isofagomine (45, IC(50) = 0.7 micro M), noeuromycin (53, IC(50) = 4 micro M), and azafagomine (54, IC(50) = 13.5 micro M) also bind strongly to the active site of GP, however, substitution on the nitrogens makes the binding weaker. The natural product five-membered iminosugar DAB (56) exhibited IC(50) approximately 0.4-0.5 micro M. Azoloperhydropyridines which can be regarded iminosugar-annelated heterocycles show moderate inhibition of GP: nojiritetrazole 12 (K(i) = 53 micro M) is the best inhibitor and fewer nitrogens in the five-membered ring weakens the binding. Physiological investigations have been carried out with N-acetyl-beta-D-glucopyranosylamine 6, spiro-thiohydantoin 18, isofagomine 45, and DAB 56 to underline the potential use of these compounds in the treatment of type 2 diabetes. Computational methods suggest to synthesize further anomerically bifunctional glucose derivatives which may be good inhibitors of GP.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cited by
Sorted by citations
Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules
Kirk, K. L. (2006) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2006.06.007 · Cited by 912
The Polar Hydrophobicity of Fluorinated Compounds
Biffinger, J. C., Kim, H. W., & DiMagno, S. G. (2004) · ChemBioChem · doi:10.1002/cbic.200300910 · Cited by 485
Zois, C. E., & Harris, A. L. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1377-9 · Cited by 267
Crataegus pinnatifida: Chemical Constituents, Pharmacology, and Potential Applications
Jia-qi, W., Peng, W., Qin, R., et al. (2014) · Molecules · doi:10.3390/molecules19021685 · Cited by 178
“concentrations in type II diabetes [87,88].”
Tactics and strategies for the synthesis of iminosugar C-glycosides: a review
Compain, P., Chagnault, V., & Martin, O. R. (2009) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2009.03.031 · Cited by 167
Sugar-mimicking glycosidase inhibitors: bioactivity and application
Asano, N. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8522-3 · Cited by 134
Targeted drugs by olefin metathesis: piperidine-based iminosugars
Drăguţan, I., Drăguţan, V., & Demonceau, A. (2011) · RSC Advances · doi:10.1039/c1ra00910a · Cited by 105
Zois, C. E., Favaro, E., & Harris, A. L. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.09.001 · Cited by 102
Wen, X., Zhang, P., Liu, J., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.10.014 · Cited by 102
Synthesis and biological activity of naturally occurring α-glucosidase inhibitors
Wardrop, D. J., & Waidyarachchi, S. L. (2010) · Natural Product Reports · doi:10.1039/b914958a · Cited by 98
Chen, J., Liu, J., Zhang, L., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.03.009 · Cited by 96
Chrysina, E. D., Kosmopoulou, M. N., Tiraidis, C., Kardakaris, R., Bischler, N., Leonidas, D. D., Hadady, Z., Somsák, L., Docsa, T., Gergely, P., et al. (2005) · Protein Science · doi:10.1110/ps.041216105 · Cited by 89
“…the basis of information derived from the crystal structure of T-state GPb– -D-glucose complex (Martin et al. 1991; Watson et al. 1994, 1995; Bichard et al. 1995; Oikonomakos et al. 1995, 2002a,b; Gregoriou et al. 1998; Somsák et al. 2001, 2003; Chrysina et al. 2003, 2004; Györgydeák et al. 2004).”
BackgroundSelf-citationAlfaro, J. A., Zheng, R. B., Persson, M., Letts, J. A., Polakowski, R., Bai, Y., Borisova, S. N., Seto, N. O. L., Lowary, T. L., Palcic, M. M., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708669200 · Cited by 87
Glycogen Phosphorylase Inhibition in Type 2 Diabetes Therapy
Baker, D. J., Timmons, J. A., & Greenhaff, P. L. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2453 · Cited by 87
“Great interest has been generated regarding the potential benefits of GPis for the treatment of type 2 diabetes because their mode of action may avoid hyperglycemic episodes (8,9,11,12,33).”
BackgroundGoyard, D., Kónya, B., Chajistamatiou, A. S., Chrysina, E. D., Leroy, J., Balzarin, S., Tournier, M., Tousch, D., Petit, P., Duret, C., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.004 · Cited by 86
Self-citationBokor, É., Docsa, T., Gergely, P., & Somsák, L. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.12.043 · Cited by 85
Self-citationBenltifa, M., Vidal, S., Gueyrard, D., Goekjian, P. G., Msaddek, M., & Praly, J. (2006) · Tetrahedron Letters · doi:10.1016/j.tetlet.2006.06.058 · Cited by 85
Glucose derived inhibitors of glycogen phosphorylase
Somsák, L. (2010) · Comptes Rendus Chimie · doi:10.1016/j.crci.2010.09.004 · Cited by 81
Self-citationWalls, A. B., Sickmann, H. M., Brown, A. M., Bouman, S. D., Ransom, B. R., Schousboe, A., & Waagepetersen, H. S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05250.x · Cited by 73
“1,4-Dideoxy-1,4-imino-D-arabinitol which structurally resembles glucose in regard to the positioning of the hydroxyl groups (Somsak et al. 2003) is a potential substrate for the glucose transporter, and consequently this was tested by measuring influx and subsequent phosphorylation of…”
BackgroundKuriyama, C., Kamiyama, O., Ikeda, K., Sanae, F., Kato, A., Adachi, I., Imahori, T., Takahata, H., Okamoto, T., & Asano, N. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.06.026 · Cited by 69
Asymmetric synthesis of 1-deoxynojirimycin and its congeners from a common chiral building block
Takahata, H., Banba, Y., Sasatani, M., et al. (2004) · Tetrahedron · doi:10.1016/j.tet.2004.06.112 · Cited by 67
A New Route to Diverse 1-Azasugars fromN-Boc-5-hydroxy-3-piperidene as a Common Building Block
Ouchi, H., Mihara, Y., & Takahata, H. (2005) · The Journal of Organic Chemistry · doi:10.1021/jo050519j · Cited by 66
Hilmi, Y., Abushama, M., Abdalgadir, H., et al. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-149 · Cited by 65
Oikonomakos, N. G., Tiraidis, C., Leonidas, D. D., Zographos, S. E., Kristiansen, M., Jessen, C. U., Nørskov‐Lauritsen, L., & Agius, L. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060496g · Cited by 65
Glycogen metabolism and the homeostatic regulation of sleep
Petit, J.-M., Burlet-Godinot, S., Magistretti, P. J., & Allaman, I. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9629-x · Cited by 79
“In vitro, DAB potently inhibits GP in different preparations (Andersen andWestergaard 2002; Somsak et al. 2003) including brain tissue homogenates (IC50≈0.”
BackgroundZhang, F., Xu, X., Zhou, B. Z., He, Z., & Zhai, Q. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027553 · Cited by 62
“Among the 28 downregulated genes, glycogen phosphorylase (Pygl) catalyzes the ratelimiting step in the degradation of glycogen in animals [14], and glycogen phosphorylase inhibitors has been proposed as potential antidiabetic agents [45].”
BackgroundBenltifa, M., Vidal, S., Fenêt, B., et al. (2006) · European Journal of Organic Chemistry · doi:10.1002/ejoc.200600073 · Cited by 62
Self-citationGyörgydeák, Z., Hadady, Z., Felföldi, N., et al. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.07.013 · Cited by 61
Self-citationWen, X., Xia, J., Cheng, K., Zhang, L., Zhang, P., Liu, J., Zhang, L., Ni, P., & Sun, H. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.08.057 · Cited by 58
Jenkinson, S. F., Best, D., Saville, A. W., Mui, J., Martínez, R. F., Nakagawa, S., Kunimatsu, T., Alonzi, D. S., Butters, T. D., Norez, C., et al. (2013) · The Journal of Organic Chemistry · doi:10.1021/jo4005487 · Cited by 49
Tamariz, J., Burgueño‐Tapia, E., Vazquez, M. A., & Delgado, F. (2018) · The Alkaloids. Chemistry and biology/The alkaloids. Chemistry and biology · doi:10.1016/bs.alkal.2018.03.001 · Cited by 54
Gergely, P. (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.464 · Cited by 47
Self-citationGlycogen phosphorylase inhibition as a therapeutic target: a review of the recent patent literature
Baker, D. J., Greenhaff, P. L., & Timmons, J. A. (2006) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.16.4.459 · Cited by 45
“Therefore, unsurprisingly, glucose analogues have been shown to be effective inhibitors of GP [34-46].”
BackgroundLetts, J. A., Rose, N. L., Fang, Y. R., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507620200 · Cited by 44
Metathesis access to monocyclic iminocyclitol-based therapeutic agents
Drăguţan, I., Drăguţan, V., Mitan, C. I., Vosloo, H. C. M., Delaude, L., & Demonceau, A. (2011) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.7.81 · Cited by 43
A General Approach to the Synthesis of 1-Deoxy- l -iminosugars
Guaragna, A., D’Errico, S., D’Alonzo, D., et al. (2007) · Organic Letters · doi:10.1021/ol7014847 · Cited by 42
Kantsadi, A. L., Bokor, É., Kun, S., Stravodimos, G. A., Chatzileontiadou, D. S. M., Leonidas, D. D., Juhász‐Tóth, É., Szakács, A., Batta, G., Docsa, T., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.06.049 · Cited by 42
“O-Perbenzylated glucosyl acetylene41 19 was cross-coupled with N-tosyl-2-iodoaniline (20) and cyclized to indole 2140 in one step.”
BackgroundMethodInfluentialSelf-citationFacile Aza‐Claisen Rearrangement of Glycals: Application in the Synthesis of 1‐Deoxy‐ L ‐iminosugars
Gupta, P., & Vankar, Y. D. (2009) · European Journal of Organic Chemistry · doi:10.1002/ejoc.200801301 · Cited by 42
Murugavel, S., Stephen, C. S. J. P., Subashini, R., et al. (2017) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2017.05.043 · Cited by 40
Kristiansen, M., Andersen, B., Iversen, L. F., & Westergaard, N. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031121n · Cited by 40
Goujon, J., Gueyrard, D., Compain, P., et al. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.12.043 · Cited by 39
Amino-functionalized iminocyclitols: synthetic glycomimetics of medicinal interest
Harit, V. K., & Ramesh, N. G. (2016) · RSC Advances · doi:10.1039/c6ra23513a · Cited by 38
Iminosugars as a new class of cholinesterase inhibitors
Decroocq, C., Stauffert, F., Pamlard, O., Oulaïdi, F., Gallienne, E., Martin, O. R., Guillou, C., & Compain, P. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.12.071 · Cited by 37
Glucose-based spiro-heterocycles as potent inhibitors of glycogen phosphorylase
Nagy, V., Benltifa, M., Vidal, S., et al. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.05.080 · Cited by 36
Self-citationLiang, Z. T., Zhang, L., Li, L., Liu, J., Li, H., Zhang, L., Chen, L., Cheng, K., Zheng, M., Wen, X., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.02.053 · Cited by 35
Efficient and Stereodivergent Syntheses of D ‐ and L ‐Fagomines and Their Analogues
Kumari, N., Reddy, B. G., & Vankar, Y. D. (2008) · European Journal of Organic Chemistry · doi:10.1002/ejoc.200800796 · Cited by 35
Aouadi, K., Jeanneau, E., Msaddek, M., et al. (2008) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2008.04.006 · Cited by 34
Lukacs, C., Oikonomakos, N. G., Crowther, R. L., Hong, L., Kammlott, R. U., Levin, W., Li, S., Liu, C., Lucas‐McGady, D., Pietranico, S., et al. (2006) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20939 · Cited by 34
Synthesis and Therapeutic Applications of Iminosugars in Cystic Fibrosis
Esposito, A., D’Alonzo, D., Fenza, M. D., Gregorio, E. D., Tamanini, A., Lippi, G., Dechecchi, M. C., & Guaragna, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093353 · Cited by 33
Schönemann, W., Gallienne, E., Compain, P., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.02.027 · Cited by 32
Sanae, F., Kamiyama, O., Ikeda‐Obatake, K., et al. (2013) · Food & Function · doi:10.1039/c3fo60514k · Cited by 32
Zhou, J., Zhang, Y., Zhou, X., Zhou, J., Zhang, L., Ye, X., & Zhang, X. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.11.036 · Cited by 32
Somsák, L., Nagy, V., Vidal, S., Czifrák, K., Berzsényi, E., & Praly, J. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.08.052 · Cited by 32
Self-citationA new asymmetric synthetic route to substituted piperidines
Reddy, M. S., Narender, M., & Rao, K. R. (2006) · Tetrahedron · doi:10.1016/j.tet.2006.10.073 · Cited by 31
A new synthetic access to bicyclic polyhydroxylated alkaloid analogues from pyranosides
Wang, N., Zhang, L., & Ye, X. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/b923180c · Cited by 31
Probing multivalency for the inhibition of an enzyme: glycogen phosphorylase as a case study
Cecioni, S., Argintaru, O.-A., Docsa, T., Gergely, P., Praly, J., & Vidal, S. (2008) · New Journal of Chemistry · doi:10.1039/b812540f · Cited by 31
Self-citationHe, L., Zhang, Y. Z., Tanoh, M., et al. (2006) · European Journal of Organic Chemistry · doi:10.1002/ejoc.200600548 · Cited by 31
Li, Q. R., Kim, S. I., Park, S. J., et al. (2013) · Tetrahedron · doi:10.1016/j.tet.2013.09.098 · Cited by 30
Inhibition of human salivary α-amylase by glucopyranosylidene-spiro-thiohydantoin
Gyémánt, G., Kandra, L., Nagy, V., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.10.119 · Cited by 30
Self-citationFerreira, F., Botuha, C., Chemla, F., et al. (2009) · The Journal of Organic Chemistry · doi:10.1021/jo802757f · Cited by 30
Synthesis of Thiohydantoin-Castanospermine Glycomimetics as Glycosidase Inhibitors
Aguilar‐Moncayo, M., Mellet, C. O., Fernández, J. M. G., & García‐Moreno, M. I. (2009) · The Journal of Organic Chemistry · doi:10.1021/jo900231b · Cited by 30
Reddy, Y. S., Kancharla, P. K., Roy, R., & Vankar, Y. D. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob06851f · Cited by 30
Alexacou, K.-M., Hayes, J. M., Tiraidis, C., Zographos, S. E., Leonidas, D. D., Chrysina, E. D., Archontis, G., Oikonomakos, N. G., Paul, J. V., Varghese, B., et al. (2007) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21837 · Cited by 30
“Glucosyltriazolylacetamide is accommodated in the catalytic site of the enzyme and the glucopyranose interacts in a manner similar to that observed in the GPb-aD-glucose complex, while the substituent group in the b-posi- tion of the C1 atom makes additional hydrogen bonding and van der Waals interactions to the prote…”
BackgroundInfluentialArora, I., Kashyap, V. K., Singh, A., Dasgupta, A., Kumar, B. N., & Shaw, A. K. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob00486h · Cited by 29
Felpin, F., Boubekeur, K., & Lebreton, J. (2004) · The Journal of Organic Chemistry · doi:10.1021/jo035522m · Cited by 29
Tetrazoles and Related Heterocycles as Promising Synthetic Antidiabetic Agents
Трифонов, Р. Е., & Ostrovskii, V. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417190 · Cited by 28
Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient
Rochester, C. D. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.305 · Cited by 29
Gupta, P., Pal, A. P. J., Reddy, Y. S., et al. (2010) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201001171 · Cited by 28
Choi, J., Yadav, N. N., & Ha, H. (2017) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.201700080 · Cited by 28
Alcaide, B., Almendros, P., Cabrero, G., et al. (2007) · The Journal of Organic Chemistry · doi:10.1021/jo701452a · Cited by 28
Glycosidase Inhibitors: Structure, Activity, Synthesis, and Medical Relevance
Bols, M., López, Ó., & Ortega‐Caballero, F. (2007) · Elsevier eBooks · doi:10.1016/b978-044451967-2/00100-8 · Cited by 30
Prasad, S. S., & Baskaran, S. (2018) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.7b02803 · Cited by 26
Blériot, Y., Simone, M. I., Wormald, M. R., et al. (2006) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2006.07.027 · Cited by 26
Synthesis of N-substituted iminosugar derivatives and their immunosuppressive activities
Zhang, G., Chen, C., Xiong, Y., et al. (2010) · Carbohydrate Research · doi:10.1016/j.carres.2010.01.021 · Cited by 26
Fazal, E., Panicker, C. Y., Varghese, H. T., et al. (2015) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2015.01.089 · Cited by 26
Saponin as regulator of biofuel: implication for ethnobotanical management of diabetes
Elekofehinti, O. O., Omotuyi, O. I., Kamdem, J. P., Ejelonu, O. C., Olher, V. G. A., Adanlawo, I. G., & da Rocha, J. B. T. (2014) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-014-0325-4 · Cited by 27
“The inhibition of glycogen phosphorylase has been proposed as one method for treating type 2 diabetes [104] since glucose production in the liver has been shown to increase in type 2 diabetes patients [81].”
MethodOtero, J. M., Soengas, R. G., Estevez, J. C., et al. (2007) · Organic Letters · doi:10.1021/ol062887v · Cited by 26
Yagodkin, A., Löschcke, K., Weisell, J., et al. (2010) · Tetrahedron · doi:10.1016/j.tet.2010.01.017 · Cited by 26
Rapid and practical synthesis of (−)-1-deoxyaltronojirimycin
Karjalainen, O. K., & Koskinen, A. M. P. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob00747a · Cited by 25
Kim, I. S., Li, Q. R., Dong, G. R., Kim, Y. C., Hong, Y. J., Lee, M., Chi, K., Oh, J. S., & Jung, Y. H. (2010) · European Journal of Organic Chemistry · doi:10.1002/ejoc.200901443 · Cited by 25
Zohreh, N., & Alizadeh, A. (2013) · ACS Combinatorial Science · doi:10.1021/co400005y · Cited by 25
Stereocontrolled synthesis of thiohydantoin spironucleosides from sugar spiroacetals
Fuentes, J. A., Salameh, B. A. B., Pradera, M. Á., et al. (2005) · Tetrahedron · doi:10.1016/j.tet.2005.09.128 · Cited by 25
Oikonomakos, N. G., Kosmopoulou, M. N., Chrysina, E. D., Leonidas, D. D., Kostas, I. D., Wendt, K. U., Klabunde, T., & Defoßa, E. (2005) · Protein Science · doi:10.1110/ps.051432405 · Cited by 25
“1) have been identified as specific targets for inhibitor binding (Somsák et al. 2001, 2003; Treadway et al. 2001; Oikonomakos 2002; Kurukulasuriya et al. 2003).”
BackgroundStereodivergent Access to Polyhydroxylated 10-Azabicyclo[4.3.1]decanes as New Calystegine Analogues
Chagnault, V., Compain, P., Lewiński, K., et al. (2009) · The Journal of Organic Chemistry · doi:10.1021/jo900235d · Cited by 24
Cheng, K., Liu, J., Sun, H., Bokor, É., Czifrák, K., Kónya, B., Tóth, M., Docsa, T., Gergely, P., & Somsák, L. (2010) · New Journal of Chemistry · doi:10.1039/b9nj00602h · Cited by 23
Self-citationSomsák, L., Felföldi, N., Kónya, B., et al. (2008) · Carbohydrate Research · doi:10.1016/j.carres.2008.01.045 · Cited by 23
Self-citationNew synthetic approaches to sugar ureas. Access to ureido-β-cyclodextrins
López, Ó., Maza, S., Maya, I., et al. (2005) · Tetrahedron · doi:10.1016/j.tet.2005.07.041 · Cited by 23
Tae, J., & Hahn, D. (2004) · Tetrahedron Letters · doi:10.1016/j.tetlet.2004.03.075 · Cited by 23
Anagnostou, E., Kosmopoulou, M. N., Chrysina, E. D., et al. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.08.010 · Cited by 23
Self-citationKumar, K. S. A., Rathee, J. S., Subramanian, M., & Chattopadhyay, S. (2013) · The Journal of Organic Chemistry · doi:10.1021/jo400448p · Cited by 23
Chacko, S., & Ramapanicker, R. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b00424 · Cited by 21
An Isofagomine Analogue with an Amidine at the Pseudoanomeric Position
Lindbäck, E., López, Ó., Fernández‐Bolaños, J. G., et al. (2011) · Organic Letters · doi:10.1021/ol200942g · Cited by 21
A facile access to ureido sugars. Synthesis of urea-bridged β-cyclodextrins
Maya, I., López, Ó., Maza, S., et al. (2003) · Tetrahedron Letters · doi:10.1016/j.tetlet.2003.09.140 · Cited by 21
Chrysina, E. D., Oikonomakos, N. G., Zographos, S. E., et al. (2003) · Biocatalysis and Biotransformation · doi:10.1080/10242420310001614360 · Cited by 21
Self-citationZhou, J. E., Negi, A., Mirallai, S. I., Warta, R., Herold‐Mende, C. C., Carty, M. P., Ye, X.-S., & Murphy, P. V. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.12.003 · Cited by 19
“These include glycosidases, glycosyltransferases [1,2], glycogen phosphorylases [3], nucleoside-processing enzymes [4], a sugar nucleotide mutase [5,6], metalloproteinases [7] and others [8].”
BackgroundBoucheron, C., Compain, P., & Martin, O. R. (2006) · Tetrahedron Letters · doi:10.1016/j.tetlet.2006.02.157 · Cited by 20
Bunik, V. I., & Aleshin, V. A. (2017) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63930-1.00011-9 · Cited by 20
Vojtech, M., Petrušová, M., Sláviková, E., et al. (2006) · Carbohydrate Research · doi:10.1016/j.carres.2006.10.019 · Cited by 20
De Masi, R., & Orlando, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137373 · Cited by 20
“This modification confers a particularly high affinity for the α-glucosidase enzyme inhibition, resulting in a clinically relevant anti-diabetic effect [230,231].”
BackgroundAnomer‐Selective Glycosidase Inhibition by 2‐ N ‐Alkylated 1‐Azafagomines
López, Ó., & Bols, M. (2007) · ChemBioChem · doi:10.1002/cbic.200700012 · Cited by 19
Metadata
- Authors
- Somsak, L., Nagy, V., Hadady, Z., Docsa, T., & Gergely, P.
- Affiliations
- University of Debrecen (HU)
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-06-01
- Volume
- 9
- Issue
- 15
- Pages
- 1177-1189
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2122174215
- Cited by
- 185
- References
- 0
- Citations by year
- 2026: 1 · 2025: 2 · 2023: 1 · 2022: 4 · 2021: 4 · 2020: 5 · 2019: 3 · 2018: 3 · 2017: 9 · 2016: 9 · 2015: 8 · 2014: 14 · 2013: 10 · 2012: 7
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- glycogen phosphorylase, antidiabetic drugs, type 2 diabetes, hydantoin derivatives, allosteric site, iminosugars, isofagomine, benzothiazole, benzimidazole, 1,3,4-oxadiazoles, tetrazoles, enzyme inhibition
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Enzyme Inhibitors, Glucose, Humans, Hypoglycemic Agents, Models, Molecular, Molecular Structure, Glycogen Phosphorylase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review